Trial Outcomes & Findings for Patient Preferences for Leadless Pacemakers (NCT NCT05327101)
NCT ID: NCT05327101
Last Updated: 2025-02-20
Results Overview
Ranking of six pacemaker device features from most concerning (1) to least concerning (6)
COMPLETED
117 participants
Baseline
2025-02-20
Participant Flow
Patients were recruited from Aveir™ DR IDE trial study sites. One-hundred seventeen patients were recruited and completed the survey instrument.
Participant milestones
| Measure |
Patient Preferences Survey
Patients were recruited from Aveir™ DR IDE trial study sites. To minimize selection bias, patients meeting the criteria listed above and agreeing to participate were asked to complete the patient-preference survey before being approached about their potential interest in enrolling in the IDE trial. Thus, they completed the patient-preference survey before they received information about dual-chamber pacemakers from the site physician and/or the Aveir™ DR IDE study and before they received a pacemaker if they ultimately received one.
|
|---|---|
|
Overall Study
STARTED
|
117
|
|
Overall Study
COMPLETED
|
117
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Patient Preferences for Leadless Pacemakers
Baseline characteristics by cohort
| Measure |
Patient Preferences Survey
n=117 Participants
Patients were recruited from Aveir™ DR IDE trial study sites. To minimize selection bias, patients meeting specified criteria and agreeing to participate were asked to complete the patient-preference survey before being approached about their potential interest in enrolling in the IDE trial. Thus, they completed the patient-preference survey before they received information about dual-chamber pacemakers from the site physician and/or the Aveir™ DR IDE study and before they received a pacemaker if they ultimately received one.
|
|---|---|
|
Age, Customized
|
67.3 years
STANDARD_DEVIATION 14.6 • n=99 Participants
|
|
Sex: Female, Male
Female
|
49 Participants
n=99 Participants
|
|
Sex: Female, Male
Male
|
68 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
2 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
113 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
2 Participants
n=99 Participants
|
|
Marital Status
Single/never married
|
7 Participants
n=99 Participants
|
|
Marital Status
Married/living as married
|
81 Participants
n=99 Participants
|
|
Marital Status
Divorced or separated
|
19 Participants
n=99 Participants
|
|
Marital Status
Widowed/surviving partner
|
9 Participants
n=99 Participants
|
|
Marital Status
Other
|
1 Participants
n=99 Participants
|
|
Health Insurance
Through a state or federal insurance exchange
|
11 participants
n=99 Participants
|
|
Health Insurance
Through my (or another person's) employer or union
|
26 participants
n=99 Participants
|
|
Health Insurance
Medicare alone
|
27 participants
n=99 Participants
|
|
Health Insurance
Medicare and supplemental insurance
|
53 participants
n=99 Participants
|
|
Health Insurance
Medicaid
|
7 participants
n=99 Participants
|
|
Health Insurance
Veterans affairs
|
6 participants
n=99 Participants
|
|
Health Insurance
Other
|
1 participants
n=99 Participants
|
|
Health Insurance
I do not have health insurance
|
2 participants
n=99 Participants
|
|
Highest Level of Education
Less than high school
|
4 Participants
n=99 Participants
|
|
Highest Level of Education
Some high school
|
3 Participants
n=99 Participants
|
|
Highest Level of Education
High school or equivalent (such as GED)
|
19 Participants
n=99 Participants
|
|
Highest Level of Education
Some college but no degree
|
22 Participants
n=99 Participants
|
|
Highest Level of Education
Technical school
|
7 Participants
n=99 Participants
|
|
Highest Level of Education
Associate's degree or 2-year college degree
|
16 Participants
n=99 Participants
|
|
Highest Level of Education
4-year college degree (such as BA, BS)
|
26 Participants
n=99 Participants
|
|
Highest Level of Education
Some graduate school but no degree
|
3 Participants
n=99 Participants
|
|
Highest Level of Education
Graduate or professional degree (such as MBA, MS, MA, MD, PhD)
|
15 Participants
n=99 Participants
|
|
Highest Level of Education
Missing
|
2 Participants
n=99 Participants
|
|
Height
|
67.8 inches
STANDARD_DEVIATION 4.5 • n=99 Participants
|
|
Weight
|
184.9 pounds
STANDARD_DEVIATION 43.5 • n=99 Participants
|
|
BMI
|
28.1 kg/m^2
STANDARD_DEVIATION 5.6 • n=99 Participants
|
|
Employment
Employed with hourly pay
|
13 Participants
n=99 Participants
|
|
Employment
Employed with salary
|
18 Participants
n=99 Participants
|
|
Employment
Self-employed
|
9 Participants
n=99 Participants
|
|
Employment
Homemaker
|
4 Participants
n=99 Participants
|
|
Employment
Student
|
1 Participants
n=99 Participants
|
|
Employment
Disabled
|
11 Participants
n=99 Participants
|
|
Employment
Not working but looking for a job
|
1 Participants
n=99 Participants
|
|
Employment
Not working and NOT looking for a job
|
1 Participants
n=99 Participants
|
|
Employment
Unable to work or on disability
|
1 Participants
n=99 Participants
|
|
Employment
Volunteer work
|
3 Participants
n=99 Participants
|
|
Employment
Other
|
0 Participants
n=99 Participants
|
|
Employment
Retired
|
68 Participants
n=99 Participants
|
|
Race
American Indian or Alaska Native
|
1 Participants
n=99 Participants
|
|
Race
Asian
|
3 Participants
n=99 Participants
|
|
Race
Black or African American
|
4 Participants
n=99 Participants
|
|
Race
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
|
Race
White
|
110 Participants
n=99 Participants
|
|
Race
Other
|
1 Participants
n=99 Participants
|
PRIMARY outcome
Timeframe: BaselinePopulation: Each respondent was asked to rank the six features (insertion procedure, pacemaker type, pacemaker location, no heavy lifting, scar on chest, and lump on chest) from most concerning (1) to least concerning (6). The table reports the mean ranking for each device feature evaluated on a scale from 1-6. The number of respondents is 90 because 27 respondents skipped the ranking questions
Ranking of six pacemaker device features from most concerning (1) to least concerning (6)
Outcome measures
| Measure |
Patient Preferences Survey
n=90 Participants
Patients were recruited from Aveir™ DR IDE trial study sites. To minimize selection bias, patients meeting the criteria listed above and agreeing to participate were asked to complete the patient-preference survey before being approached about their potential interest in enrolling in the IDE trial. Thus, they completed the patient-preference survey before they received information about dual-chamber pacemakers from the site physician and/or the Aveir™ DR IDE study and before they received a pacemaker if they ultimately received one.
|
|---|---|
|
Mean Rankings for Pacemaker Device Features
Insertion procedure
|
2.3 score on a scale
Standard Deviation 1.3
|
|
Mean Rankings for Pacemaker Device Features
Pacemaker type
|
2.6 score on a scale
Standard Deviation 1.2
|
|
Mean Rankings for Pacemaker Device Features
Pacemaker location
|
2.2 score on a scale
Standard Deviation 1.0
|
|
Mean Rankings for Pacemaker Device Features
No heavy lifting for 6 weeks
|
4.7 score on a scale
Standard Deviation 1.5
|
|
Mean Rankings for Pacemaker Device Features
Scar on chest
|
5.1 score on a scale
Standard Deviation 1.0
|
|
Mean Rankings for Pacemaker Device Features
Lump on chest
|
4.1 score on a scale
Standard Deviation 1.4
|
PRIMARY outcome
Timeframe: BaselineThe preference weights for the RPL model. Effect-coded parameters generate log-odds preference weights representing the relative strength of preference for each attribute level versus the mean effect across levels normalized at zero. A higher weight indicates a more preferred level while a lower weight indicates a less preferred level.
Outcome measures
| Measure |
Patient Preferences Survey
n=117 Participants
Patients were recruited from Aveir™ DR IDE trial study sites. To minimize selection bias, patients meeting the criteria listed above and agreeing to participate were asked to complete the patient-preference survey before being approached about their potential interest in enrolling in the IDE trial. Thus, they completed the patient-preference survey before they received information about dual-chamber pacemakers from the site physician and/or the Aveir™ DR IDE study and before they received a pacemaker if they ultimately received one.
|
|---|---|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions - Preference Weights (Effect-coded Parameters)
Pacemaker type - Leadless, removable
|
0.340 preference weights
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions - Preference Weights (Effect-coded Parameters)
Pacemaker type - Leadless, non-removable
|
-0.310 preference weights
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions - Preference Weights (Effect-coded Parameters)
Pacemaker type - Transvenous
|
-0.030 preference weights
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions - Preference Weights (Effect-coded Parameters)
Battery life - 15 years
|
0.454 preference weights
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions - Preference Weights (Effect-coded Parameters)
Battery life - 12 years
|
0.253 preference weights
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions - Preference Weights (Effect-coded Parameters)
Battery life - 8 years
|
-0.235 preference weights
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions - Preference Weights (Effect-coded Parameters)
Battery life - 5 years
|
-0.473 preference weights
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions - Preference Weights (Effect-coded Parameters)
Time since regulatory approval - 10 years
|
0.212 preference weights
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions - Preference Weights (Effect-coded Parameters)
Time since regulatory approval - 2 years
|
-0.212 preference weights
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions - Preference Weights (Effect-coded Parameters)
Discomfort for 6 months - No discomfort
|
0.099 preference weights
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions - Preference Weights (Effect-coded Parameters)
Discomfort for 6 months - Discomfort
|
-0.099 preference weights
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions - Preference Weights (Effect-coded Parameters)
Risk of Complication - 1%
|
0.957 preference weights
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions - Preference Weights (Effect-coded Parameters)
Risk of Complication - 5%
|
0.396 preference weights
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions - Preference Weights (Effect-coded Parameters)
Risk of Complication - 10%
|
-0.390 preference weights
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions - Preference Weights (Effect-coded Parameters)
Risk of Complication - 20%
|
-0.963 preference weights
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions - Preference Weights (Effect-coded Parameters)
Risk of infection - 1%
|
0.961 preference weights
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions - Preference Weights (Effect-coded Parameters)
Risk of infection - 5%
|
0.408 preference weights
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions - Preference Weights (Effect-coded Parameters)
Risk of infection - 10%
|
-0.132 preference weights
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions - Preference Weights (Effect-coded Parameters)
Risk of infection - 20%
|
-1.237 preference weights
|
PRIMARY outcome
Timeframe: BaselineThe standard deviations representing the degree of variation in preference weights, with larger estimates representing preference heterogeneity.
Outcome measures
| Measure |
Patient Preferences Survey
n=117 Participants
Patients were recruited from Aveir™ DR IDE trial study sites. To minimize selection bias, patients meeting the criteria listed above and agreeing to participate were asked to complete the patient-preference survey before being approached about their potential interest in enrolling in the IDE trial. Thus, they completed the patient-preference survey before they received information about dual-chamber pacemakers from the site physician and/or the Aveir™ DR IDE study and before they received a pacemaker if they ultimately received one.
|
|---|---|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions- Standard Deviations
Pacemaker type - Leadless, removable
|
0.490 standard deviation
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions- Standard Deviations
Pacemaker type - Leadless, non-removable
|
1.411 standard deviation
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions- Standard Deviations
Pacemaker type - Transvenous
|
0.921 standard deviation
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions- Standard Deviations
Battery life - 15 years
|
0.562 standard deviation
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions- Standard Deviations
Battery life - 12 years
|
0.420 standard deviation
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions- Standard Deviations
Battery life - 8 years
|
0.242 standard deviation
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions- Standard Deviations
Battery life - 5 years
|
0.741 standard deviation
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions- Standard Deviations
Time since regulatory approval - 10 years
|
0.345 standard deviation
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions- Standard Deviations
Time since regulatory approval - 2 years
|
0.345 standard deviation
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions- Standard Deviations
Discomfort for 6 months - No discomfort
|
0.121 standard deviation
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions- Standard Deviations
Discomfort for 6 months - Discomfort
|
0.121 standard deviation
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions- Standard Deviations
Risk of Complication - 1%
|
0.606 standard deviation
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions- Standard Deviations
Risk of Complication - 5%
|
0.346 standard deviation
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions- Standard Deviations
Risk of Complication - 10%
|
0.838 standard deviation
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions- Standard Deviations
Risk of Complication - 20%
|
1.790 standard deviation
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions- Standard Deviations
Risk of infection - 1%
|
0.683 standard deviation
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions- Standard Deviations
Risk of infection - 5%
|
0.293 standard deviation
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions- Standard Deviations
Risk of infection - 10%
|
0.077 standard deviation
|
|
Results From RPL Model of Discrete Choice Experiment Choice Questions- Standard Deviations
Risk of infection - 20%
|
1.052 standard deviation
|
PRIMARY outcome
Timeframe: BaselineMaximum-acceptable risk (MAR) of a complication was calculated for patients based off latent-class analysis with two groups-leadless class and transvenous class (see secondary outcome Constrained 2-class Latent-class model preference weights). The MAR represents risk level patients would be willing to accept to obtain their preferred pacemaker type, no discomfort, a device with longer battery life, and a device with more time since regulatory approval.
Outcome measures
| Measure |
Patient Preferences Survey
n=117 Participants
Patients were recruited from Aveir™ DR IDE trial study sites. To minimize selection bias, patients meeting the criteria listed above and agreeing to participate were asked to complete the patient-preference survey before being approached about their potential interest in enrolling in the IDE trial. Thus, they completed the patient-preference survey before they received information about dual-chamber pacemakers from the site physician and/or the Aveir™ DR IDE study and before they received a pacemaker if they ultimately received one.
|
|---|---|
|
Maximum-acceptable Risks of a Complication
Patients in leadless class willing to accept MAR for removable leadless rather than transvenous
|
13.4 percentage of maximum-acceptable risk
Interval 6.4 to 23.8
|
|
Maximum-acceptable Risks of a Complication
Patients in transvenous class willing to accept MAR for removable leadless rather than transvenous
|
0 percentage of maximum-acceptable risk
Interval 0.0 to 0.0
|
|
Maximum-acceptable Risks of a Complication
Patients in leadless class willing to accept MAR for transvenous rather than removable leadless
|
0 percentage of maximum-acceptable risk
Interval 0.0 to 0.0
|
|
Maximum-acceptable Risks of a Complication
Patients in transvenous class willing to accept MAR for transvenous rather than removable leadless
|
7.6 percentage of maximum-acceptable risk
Interval 1.7 to 16.8
|
|
Maximum-acceptable Risks of a Complication
Patients in leadless class willing to accept MAR for transvenous rather than nonremovable leadless
|
0 percentage of maximum-acceptable risk
Interval 0.0 to 0.0
|
|
Maximum-acceptable Risks of a Complication
Patients in transvenous class willing to accept MAR for transvenous instead of nonremovable leadless
|
14.5 percentage of maximum-acceptable risk
Interval 7.3 to 36.6
|
|
Maximum-acceptable Risks of a Complication
Patients in leadless class willing to accept MAR for removable rather than nonremovable leadless
|
5.1 percentage of maximum-acceptable risk
Interval 0.4 to 9.2
|
|
Maximum-acceptable Risks of a Complication
Patients in transvenous class willing to accept MAR for removable rather than nonremovable leadless
|
6.3 percentage of maximum-acceptable risk
Interval 2.4 to 10.5
|
|
Maximum-acceptable Risks of a Complication
Transvenous class patients willing to accept MAR for 10 yrs since government approval rather than 2
|
0.7 percentage of maximum-acceptable risk
Interval -2.0 to 3.7
|
|
Maximum-acceptable Risks of a Complication
Leadless class patients willing to accept MAR for 10 yrs since government approval rather than 2
|
6.8 percentage of maximum-acceptable risk
Interval 3.6 to 10.1
|
|
Maximum-acceptable Risks of a Complication
Leadless & transvenous class patients willing to accept MAR for 15 yrs of battery life instead of 2
|
6.7 percentage of maximum-acceptable risk
Interval 3.9 to 9.9
|
|
Maximum-acceptable Risks of a Complication
Leadless & transvenous class patients willing to accept MAR for no discomfort rather than discomfort
|
2.0 percentage of maximum-acceptable risk
Interval 0.5 to 4.1
|
PRIMARY outcome
Timeframe: BaselineMaximum-acceptable risk (MAR) of an infection was calculated for patients based off latent-class analysis with two groups-leadless class and transvenous class (see secondary outcome Constrained 2-class Latent-class model preference weights). The MAR represent the risk that patients would be willing to accept to obtain their preferred pacemaker type, no discomfort, a device with longer battery life, and a device with more time since regulatory approval.
Outcome measures
| Measure |
Patient Preferences Survey
n=117 Participants
Patients were recruited from Aveir™ DR IDE trial study sites. To minimize selection bias, patients meeting the criteria listed above and agreeing to participate were asked to complete the patient-preference survey before being approached about their potential interest in enrolling in the IDE trial. Thus, they completed the patient-preference survey before they received information about dual-chamber pacemakers from the site physician and/or the Aveir™ DR IDE study and before they received a pacemaker if they ultimately received one.
|
|---|---|
|
Maximum-acceptable Risks of an Infection
Patients in leadless class willing to accept MAR for removable leadless rather than transvenous
|
16.8 percentage of maximum-acceptable risk
Interval 7.6 to 28.9
|
|
Maximum-acceptable Risks of an Infection
Patients in transvenous class willing to accept MAR for removable leadless rather than transvenous
|
0 percentage of maximum-acceptable risk
Interval 0.0 to 0.0
|
|
Maximum-acceptable Risks of an Infection
Patients in leadless class willing to accept MAR for transvenous rather than removable leadless
|
0 percentage of maximum-acceptable risk
Interval 0.0 to 0.0
|
|
Maximum-acceptable Risks of an Infection
Patients in transvenous class willing to accept MAR for transvenous rather than removable leadless
|
8.9 percentage of maximum-acceptable risk
Interval 1.5 to 21.6
|
|
Maximum-acceptable Risks of an Infection
Patients in leadless class willing to accept MAR for transvenous rather than nonremovable leadless
|
0 percentage of maximum-acceptable risk
Interval 0.0 to 0.0
|
|
Maximum-acceptable Risks of an Infection
Patients in transvenous class willing to accept MAR for transvenous instead of nonremovable leadless
|
17.8 percentage of maximum-acceptable risk
Interval 8.5 to 38.3
|
|
Maximum-acceptable Risks of an Infection
Patients in leadless class willing to accept MAR for removable rather than nonremovable leadless
|
4.7 percentage of maximum-acceptable risk
Interval 0.5 to 11.5
|
|
Maximum-acceptable Risks of an Infection
Patients in transvenous class willing to accept MAR for removable rather than nonremovable leadless
|
6.6 percentage of maximum-acceptable risk
Interval 2.4 to 13.3
|
|
Maximum-acceptable Risks of an Infection
Transvenous class patients willing to accept MAR for 10 yrs since government approval rather than 2
|
0.8 percentage of maximum-acceptable risk
Interval -1.6 to 3.1
|
|
Maximum-acceptable Risks of an Infection
Leadless class patients willing to accept MAR for 10 yrs since government approval rather than 2
|
7.6 percentage of maximum-acceptable risk
Interval 3.5 to 14.0
|
|
Maximum-acceptable Risks of an Infection
Leadless & transvenous class patients willing to accept MAR for 15 yrs of battery life instead of 2
|
7.5 percentage of maximum-acceptable risk
Interval 3.8 to 12.6
|
|
Maximum-acceptable Risks of an Infection
Leadless & transvenous class patients willing to accept MAR for no discomfort rather than discomfort
|
1.9 percentage of maximum-acceptable risk
Interval 0.6 to 3.6
|
PRIMARY outcome
Timeframe: BaselinePreference weight estimates were used to calculate the predicted probabilities that patients would choose a hypothetical pacemaker profile out of three different pacemaker types- leadless pacemaker removable, leadless pacemaker non-removable, or pacemaker with leads. Attributes for each pacemaker profile were defined using historical or published values. Preference weights from the latent class model were used to compute the probability that respondents within each class preference would choose a pacemaker profile over another.
Outcome measures
| Measure |
Patient Preferences Survey
n=117 Participants
Patients were recruited from Aveir™ DR IDE trial study sites. To minimize selection bias, patients meeting the criteria listed above and agreeing to participate were asked to complete the patient-preference survey before being approached about their potential interest in enrolling in the IDE trial. Thus, they completed the patient-preference survey before they received information about dual-chamber pacemakers from the site physician and/or the Aveir™ DR IDE study and before they received a pacemaker if they ultimately received one.
|
|---|---|
|
Probability of Choosing Specified Pacemakers - All 3 Profiles
Probability leadless class to choose profile: leadless pacemaker removable
|
41.7 percentage of probability
Interval 31.2 to 50.5
|
|
Probability of Choosing Specified Pacemakers - All 3 Profiles
Probability transvenous class to choose profile: leadless pacemaker removable
|
8.0 percentage of probability
Interval 2.9 to 19.4
|
|
Probability of Choosing Specified Pacemakers - All 3 Profiles
Probability leadless class to choose profile: leadless pacemaker non-removable
|
27.4 percentage of probability
Interval 16.7 to 39.8
|
|
Probability of Choosing Specified Pacemakers - All 3 Profiles
Probability transvenous class to choose profile: leadless pacemaker non-removable
|
4.5 percentage of probability
Interval 1.7 to 10.9
|
|
Probability of Choosing Specified Pacemakers - All 3 Profiles
Probability leadless class to choose profile: pacemaker with leads
|
30.9 percentage of probability
Interval 16.9 to 48.9
|
|
Probability of Choosing Specified Pacemakers - All 3 Profiles
Probability transvenous class to choose profile: pacemaker with leads
|
87.5 percentage of probability
Interval 70.1 to 95.3
|
PRIMARY outcome
Timeframe: BaselinePreference weight estimates were used to calculate the predicted probabilities that patients would choose a hypothetical pacemaker profile out of three different pacemaker types- leadless pacemaker removable or leadless pacemaker non-removable. Attributes for each pacemaker profile were defined using historical or published values. Preference weights from the latent class model were used to compute the probability that respondents within each class preference would choose a pacemaker profile over another.
Outcome measures
| Measure |
Patient Preferences Survey
n=117 Participants
Patients were recruited from Aveir™ DR IDE trial study sites. To minimize selection bias, patients meeting the criteria listed above and agreeing to participate were asked to complete the patient-preference survey before being approached about their potential interest in enrolling in the IDE trial. Thus, they completed the patient-preference survey before they received information about dual-chamber pacemakers from the site physician and/or the Aveir™ DR IDE study and before they received a pacemaker if they ultimately received one.
|
|---|---|
|
Probability of Choosing Specified Pacemakers - Leadless Pacemaker Removable vs. Leadless Pacemaker Non-removable
Probability leadless class to choose profile: leadless pacemaker removable
|
60.4 percentage of probability
Interval 48.7 to 70.7
|
|
Probability of Choosing Specified Pacemakers - Leadless Pacemaker Removable vs. Leadless Pacemaker Non-removable
Probability transvenous class to choose profile: leadless pacemaker removable
|
64.0 percentage of probability
Interval 54.3 to 72.7
|
|
Probability of Choosing Specified Pacemakers - Leadless Pacemaker Removable vs. Leadless Pacemaker Non-removable
Probability leadless class to choose profile: leadless pacemaker non-removable
|
39.6 percentage of probability
Interval 29.3 to 51.3
|
|
Probability of Choosing Specified Pacemakers - Leadless Pacemaker Removable vs. Leadless Pacemaker Non-removable
Probability transvenous class to choose profile: leadless pacemaker non-removable
|
36 percentage of probability
Interval 27.3 to 45.7
|
PRIMARY outcome
Timeframe: BaselinePreference weight estimates were used to calculate the predicted probabilities that patients would choose a hypothetical pacemaker profile out of three different pacemaker types- leadless pacemaker removable or pacemaker with leads. Attributes for each pacemaker profile were defined using historical or published values. Preference weights from the latent class model were used to compute the probability that respondents within each class preference would choose a pacemaker profile over another.
Outcome measures
| Measure |
Patient Preferences Survey
n=117 Participants
Patients were recruited from Aveir™ DR IDE trial study sites. To minimize selection bias, patients meeting the criteria listed above and agreeing to participate were asked to complete the patient-preference survey before being approached about their potential interest in enrolling in the IDE trial. Thus, they completed the patient-preference survey before they received information about dual-chamber pacemakers from the site physician and/or the Aveir™ DR IDE study and before they received a pacemaker if they ultimately received one.
|
|---|---|
|
Probability of Choosing Specified Pacemakers - Leadless Pacemaker Removable vs. Pacemaker With Leads
Probability leadless class to choose profile: leadless pacemaker removable
|
57.4 percentage of probability
Interval 39.6 to 73.7
|
|
Probability of Choosing Specified Pacemakers - Leadless Pacemaker Removable vs. Pacemaker With Leads
Probability transvenous class to choose profile: leadless pacemaker removable
|
8.4 percentage of probability
Interval 3.0 to 21.6
|
|
Probability of Choosing Specified Pacemakers - Leadless Pacemaker Removable vs. Pacemaker With Leads
Probability leadless class to choose profile: pacemaker with leads
|
42.6 percentage of probability
Interval 26.3 to 60.4
|
|
Probability of Choosing Specified Pacemakers - Leadless Pacemaker Removable vs. Pacemaker With Leads
Probability transvenous class to choose profile: pacemaker with leads
|
91.6 percentage of probability
Interval 78.3 to 97.0
|
PRIMARY outcome
Timeframe: BaselinePreference weight estimates were used to calculate the predicted probabilities that patients would choose a hypothetical pacemaker profile out of three different pacemaker types- leadless pacemaker non-removable or pacemaker with leads. Attributes for each pacemaker profile were defined using historical or published values. Preference weights from the latent class model were used to compute the probability that respondents within each class preference would choose a pacemaker profile over another.
Outcome measures
| Measure |
Patient Preferences Survey
n=117 Participants
Patients were recruited from Aveir™ DR IDE trial study sites. To minimize selection bias, patients meeting the criteria listed above and agreeing to participate were asked to complete the patient-preference survey before being approached about their potential interest in enrolling in the IDE trial. Thus, they completed the patient-preference survey before they received information about dual-chamber pacemakers from the site physician and/or the Aveir™ DR IDE study and before they received a pacemaker if they ultimately received one.
|
|---|---|
|
Probability of Choosing Specified Pacemakers - Leadless Pacemaker Non-removable vs. Pacemaker With Leads
Probability leadless class to choose profile: leadless pacemaker non-removable
|
46.9 percentage of probability
Interval 26.2 to 69.1
|
|
Probability of Choosing Specified Pacemakers - Leadless Pacemaker Non-removable vs. Pacemaker With Leads
Probability transvenous class to choose profile: leadless pacemaker non-removable
|
4.9 percentage of probability
Interval 1.7 to 13.4
|
|
Probability of Choosing Specified Pacemakers - Leadless Pacemaker Non-removable vs. Pacemaker With Leads
Probability leadless class to choose profile: pacemaker with leads
|
53.1 percentage of probability
Interval 30.8 to 73.8
|
|
Probability of Choosing Specified Pacemakers - Leadless Pacemaker Non-removable vs. Pacemaker With Leads
Probability transvenous class to choose profile: pacemaker with leads
|
95.1 percentage of probability
Interval 86.6 to 98.2
|
SECONDARY outcome
Timeframe: BaselineLatent-class (LC) analysis was used to identify systematically different preference patterns across respondents. LC analysis provides a unique set of estimates of preference weights for a prespecified number of preference classes. Respondents are probabilistically assigned to classes based on the similarity of their responses to the overall preference pattern identified in each class.
Outcome measures
| Measure |
Patient Preferences Survey
n=117 Participants
Patients were recruited from Aveir™ DR IDE trial study sites. To minimize selection bias, patients meeting the criteria listed above and agreeing to participate were asked to complete the patient-preference survey before being approached about their potential interest in enrolling in the IDE trial. Thus, they completed the patient-preference survey before they received information about dual-chamber pacemakers from the site physician and/or the Aveir™ DR IDE study and before they received a pacemaker if they ultimately received one.
|
|---|---|
|
Constrained 2-class Latent-class Model Preference Weights
Leadless Class
|
50.5 percentage of participants
|
|
Constrained 2-class Latent-class Model Preference Weights
Transvenous class
|
49.6 percentage of participants
|
SECONDARY outcome
Timeframe: BaselineNumber of Discrete choice experiment (DCE) questions answered by 117 respondents who answered at least the first 8 DCE questions. After respondents answered 8 DCE questions, they were asked if they would like to complete 4 additional questions.
Outcome measures
| Measure |
Patient Preferences Survey
n=117 Participants
Patients were recruited from Aveir™ DR IDE trial study sites. To minimize selection bias, patients meeting the criteria listed above and agreeing to participate were asked to complete the patient-preference survey before being approached about their potential interest in enrolling in the IDE trial. Thus, they completed the patient-preference survey before they received information about dual-chamber pacemakers from the site physician and/or the Aveir™ DR IDE study and before they received a pacemaker if they ultimately received one.
|
|---|---|
|
Number of Discrete Choice Experiment Questions Answered
8 questions
|
41 Participants
|
|
Number of Discrete Choice Experiment Questions Answered
12 questions
|
76 Participants
|
SECONDARY outcome
Timeframe: BaselineRespondent characteristics can be associated with class membership probabilities to "profile" the classes. These results show if respondents with certain characteristics are more likely to be in one class versus the other. The odds ratios of being in the transvenous class versus the leadless class for patient characteristics. Odds ratios greater than 1 indicate a higher likelihood of being in the class preferring transvenous pacemakers and pacemakers with longer time since government approval.
Outcome measures
| Measure |
Patient Preferences Survey
n=117 Participants
Patients were recruited from Aveir™ DR IDE trial study sites. To minimize selection bias, patients meeting the criteria listed above and agreeing to participate were asked to complete the patient-preference survey before being approached about their potential interest in enrolling in the IDE trial. Thus, they completed the patient-preference survey before they received information about dual-chamber pacemakers from the site physician and/or the Aveir™ DR IDE study and before they received a pacemaker if they ultimately received one.
|
|---|---|
|
Association of Patient Characteristics With Membership in the Transvenous Class Versus the Leadless Class
Male
|
1.15 odds ratio
|
|
Association of Patient Characteristics With Membership in the Transvenous Class Versus the Leadless Class
Age, per 1-year increase
|
0.99 odds ratio
|
|
Association of Patient Characteristics With Membership in the Transvenous Class Versus the Leadless Class
BMI, per unit increase
|
1.05 odds ratio
|
|
Association of Patient Characteristics With Membership in the Transvenous Class Versus the Leadless Class
Major surgery requiring hospitalization in the last 5 years
|
1.55 odds ratio
|
|
Association of Patient Characteristics With Membership in the Transvenous Class Versus the Leadless Class
Sedentary lifestyle with light activity
|
2.73 odds ratio
|
|
Association of Patient Characteristics With Membership in the Transvenous Class Versus the Leadless Class
Interaction of lifestyle and BMI
|
0.98 odds ratio
|
Adverse Events
Patient Preferences Survey
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place